Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 8/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.57 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7541416 | 0.95 | SLC9A1 (0.71) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL12676393 | 0.93 | SLC9A1 (0.71) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL20244273 | 0.93 | SLC9A1 (0.71) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL18636772 | 0.93 | SLC9A1 (0.71) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL18636614 | 0.89 | SLC9A1 (0.68) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL14796568 | 0.89 | SLC9A1 (0.79) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL730645 | 0.82 | SLC9A1 (0.70) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL7667065 | 0.82 | SLC9A1 (0.70) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL7011474 | 0.82 | SLC9A1 (0.70) | SLC9A1NPC1RAB9AMAPTGLA | |
| SCHEMBL1834794 | 0.82 | SLC9A1 (1.00) | SLC9A1NPC1RAB9AMAPTGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113357-A1 | Muscarinic agonists | ANDERSON CARL-MAGNUS A (DK) | 2005-05-26 | — | — | US | claimed |
| CN-1439002-A | Muscarinic agonists | ACADIA PHARM INC (US) | 2003-08-27 | — | — | CN | claimed |
| EP-1278741-A1 | MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2003-01-29 | — | — | EP | claimed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | claimed |
| WO-2001083472-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| CN-107849035-A | Phenyl heterocyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-107074833-A | With β2The Benzocyclodirivative of receptor agonism and M3 receptor antagonist activities and its in purposes pharmaceutically | 四川海思科制药有限公司 | 2017-08-18 | — | — | CN | disclosed |
| EP-3141582-A1 | SYNTHESIS AND USE OF POLYALKYLAMINES | Incella GmbH (DE) | 2017-03-15 | — | — | EP | disclosed |
| CN-101016296-A | Muscarinic agonists | ACADIA PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
| US-20070155795-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7238713-B2 | Muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| CN-1814596-A | Muscarinic agonists | ARCADIA PHARMACEUTICALS INC (US) | 2006-08-09 | — | — | CN | disclosed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2001083472-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | disclosed |
| US-4175129-A | Antiemetic 1-(benzoxazolylalkyl)-piperidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-11-20 | — | — | US | disclosed |
| US-4160836-A | Antiemetic 1-(benzothiazolylalkyl)piperidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-07-10 | — | — | US | disclosed |
| US-4126687-A | ANTIEMETIC, 1-(BENZIMIDAZOLYL-ALKYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1978-11-21 | — | — | US | disclosed |
| US-4126688-A | ANTIEMETIC 1-(BENZOTRIAZOLYL-ALKYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1978-11-21 | — | — | US | disclosed |
| US-4110333-A | ANTIEMETIC INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1978-08-29 | — | — | US | disclosed |
| US-4066772-A | ANTIEMETICS | JANSSEN PHARMACEUTICA N.V. (BE) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037886-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | SLC9A1 3562/4885NPC1 1418/4885RAB9A 2681/4885 |
| US-20070155795-A1 | MUSCARINIC AGONISTS | CHRM2, CHRM1, CHRM4 | SLC9A1 3562/4885NPC1 1418/4885RAB9A 2681/4885 |
| US-20050113357-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | SLC9A1 3562/4885NPC1 1418/4885RAB9A 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.